Zobrazeno 1 - 6
of 6
pro vyhledávání: '"María Ruiz de Arcos"'
Autor:
Ana Nogales-Nieves, María José López-Urbano, Feliciana Valle-Martín, Beatriz Bullón-Fernández, Irene Mármol-Szombathy, Emilio Domínguez-Durán, Ana Palomo-Sánchez, Serafín Sánchez-Gómez, Blas Poyatos-Poyatos, Fátima Alarcón-Balanza, María Ruiz-de Arcos, María Teresa Manjón-Collado, Antonio Mora-Quintero, Estela Palmero-Olmo
Publikováno v:
Acta Otorrinolaringológica Española. 72:11-20
Resumen Antecedentes y objetivo Actualmente, no existen series de pacientes que hayan descrito la incidencia de cada una de las enfermedades que causan alteraciones del equilibrio (AE) en atencion primaria. El objetivo de este estudio es calcular la
Autor:
Ana Palomo-Sánchez, Irene Mármol-Szombathy, Estela Palmero-Olmo, María Ruiz-de Arcos, Fátima Alarcón-Balanza, María Teresa Manjón-Collado, Ana Nogales-Nieves, María José López-Urbano, Blas Poyatos-Poyatos, Beatriz Bullón-Fernández, Antonio Mora-Quintero, Emilio Domínguez-Durán, Feliciana Valle-Martín, Serafín Sánchez-Gómez
Publikováno v:
Acta Otorrinolaringologica (English Edition). 72:11-20
Background and objective In our country, there are no series of patients that have described the incidence of the different diseases which cause balance disorders (BD) in primary care. The objective of this study is to calculate the incidence of each
Autor:
Rocío López Ruiz, María Ruiz de Arcos, Félix Sánchez Fernández, Guillermo Navarro Mascarell, Sara Eichau, Juan Luis Ruiz Peña, Juan Diego Guerra Hiraldo, Julio Dotor García-Soto, Alejandro Fuerte Hortigón, M Dolores Páramo Camino
Publikováno v:
Neurol Clin Pract
Background and Objective:The most common adverse events following Alemtuzumab include adverse infusion reactions, infections and autoimmune disorders. Skin adverse events are common during infusion but there are few reported cases of long-term skin a
Autor:
Rocío López Ruiz, Juan Diego Guerra Hiraldo, Julio Dotor García-Soto, Félix Sánchez Fernández, María Ruiz de Arcos, Sara Eichau Madueño
Publikováno v:
Revista de Neurología. 75:123
Autor:
Sara Eichau, Rocío López Ruiz, María Ruíz de Arcos, Juan Luis Ruiz-Peña, Guillermo Navarro, Miguel Ángel Calleja, José Luis Moreno-Amador, Julio Dotor García-Soto
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses. The objective of this study was to describe the
Externí odkaz:
https://doaj.org/article/094fc9f9f7414c1781855e49921d42f0
Autor:
Santos García D., Teresa de Deus Fonticoba, Carlos Cores, Guillermo Muñoz, Jose M. Paz González, Cristina Martínez Miró, Ester Suárez, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluis Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Inés Legarda, Jorge Hernández Vara, Iria Cabo, Luis López Manzanares, Isabel González Aramburu, María A. Ávila Rivera, Maria J. Catalán, Víctor Nogueira, Víctor Puente, María Ruíz de Arcos, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonso, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Pedro Clavero, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Carlos Ordás, Luis M. López Díaz, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, COPPADIS Study Group
Publikováno v:
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment i
Externí odkaz:
https://doaj.org/article/f6dde4dc0dad4c5f8c95e81a9fb5163e